STUDY QUESTION: Is there a synergistic risk of severe maternal morbidity (SMM) in overweight/obese women who conceived by IVF compared to normal-weight women without IVF?
Introduction
The epidemic of overweight (BMI = 25-29.9 kg/m 2 ) and obesity (BMI ≥30 kg/m 2 ) affects 19 and 25% of reproductive aged women in Canada, respectively (Statistics Canada, 2015, 27 November) , and similar proportions in the UK (UK National Health Statistics, 2017). Overweight and obesity contribute to female infertility due to oligoanovulation, smaller or fewer oocytes and polycystic ovarian syndrome (PCOS), thus it is not uncommon for overweight and obese women to seek fertility therapy such as IVF (Koning et al., 2012) . Moreover, repeated cycles of ovarian stimulation are often required to achieve pregnancy in obese women (Fedorcsak et al., 2001) . There is a doserelated increase in the risk of various maternal complications with increasing BMI (El-Chaar et al., 2013 , Witteveen et al., 2013 , but whether these pregnancy complications are further increased after IVF is not known. Both IVF and high BMI are potential determinants of severe maternal morbidity (SMM), a broad composite health outcome used to describe a severely ill woman who either died or experienced a near-fatal event during, or within 42 days, of pregnancy. Its use increasingly replaces maternal mortality as an obstetric quality indicator in high income countries (Firoz et al., 2013) . Recent reports suggest that SMM rates are climbing in Canada (Public Health Agency of Canada, 2013) and in the USA (MacDorman and Declercq, 2017) . In a recent analysis of 1 million US deliveries, researchers found a 2.3-fold higher risk of SMM (95% CI: 2.10-2.67) in ART as compared to non-ART pregnancies. (Martin et al., 2016) . Findings were similar in two other studies (Belanoff et al., 2016 , Wang et al., 2016 . In these studies, obesity was either partially captured using diagnostic codes (Martin et al., 2016) , not recorded (Belanoff et al., 2016) or recorded in small numbers (Wang et al., 2016) , and SMM was not analyzed according to maternal BMI.
Since assisted reproduction is increasing in use, and partially subsidized within Canada (Tulandi and King, 2013) and elsewhere (Pandey and Bhattacharya, 2010) , costs, success rates and health outcomes associated with treatment in overweight and obese women are being considered in treatment decisions (Koning et al., 2010, Pandey and Bhattacharya, 2010) . It is important to characterize whether SMM and other maternal complications increase further after IVF to aid in these decisions. We sought to estimate the individual and combined effects of increased BMI and conception through IVF on SMM and other maternal outcomes, and to evaluate for a statistical interaction between these two factors.
Materials and Methods

Study design and data sources
In this population-based cohort study, we analyzed data from the Ontario birth registry (BORN Information System) linked via unique patient identifiers with Ontario records from the Canadian Assisted Reproductive Technologies Register (CARTR-Plus). The BORN Information System data are subject to an ongoing program of quality checks, verifications and formal training sessions for individuals collecting and entering data. Prior quality audits have indicated capture of >99% of hospital deliveries in the province and high data quality (BORN Ontario, 2016, April) . CARTR-Plus contains information on the use of fertility treatments, clinical pregnancy and live birth rates from all assisted reproductive centers in Canada. Its recent linkage with the BORN Information System ensures that prenatal, antenatal and delivery indicators are recorded for all women who achieved a viable intrauterine pregnancy by IVF.
Patient data was linked with the Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD) to ascertain maternal chronic health conditions and outcomes using International Classification of Diseases, 10th Revision (ICD-10-CA) and Canadian Classification of Health Interventions (CCI) codes. These complex validated linkage algorithms serve to provide a comprehensive, robust and clinically relevant picture of maternal health outcomes in Canadian IVF pregnancies.
Study population
Women who delivered a live or stillborn infant weighing ≥500 g at ≥20 weeks gestation were eligible for inclusion in the cohort if they conceived within the 1-year study period (embryo transfer date from 11 January 2013 to 10 January 2014 for IVF pregnancies; estimated date of conception (EDC) from 11 January 2013 to 10 January 2014 for non-IVF pregnancies, estimated by subtracting gestational age from date of birth and adding 14 days (Darrow et al., 2009) ). We excluded women younger than age 18 years or with missing maternal age, those with multiple gestations, elective terminations or ectopic or molar pregnancies, and if another form of ART was used. We further restricted the cohort to women who conceived at least 43 weeks before 31 October 2014 (our last expected birth) to avoid oversampling short pregnancies toward the end of the study period (Barnett, 2011) .
Study exposures
We considered two exposures: IVF pregnancy as recorded in CARTR-Plus (including ICSI; both fresh and frozen transfers) and elevated BMI.
Pre-pregnancy BMI was derived using height and pre-pregnancy weight. Weight was captured from several sources: at the first antenatal visit with an obstetrics care provider, at the first visit with a fertility specialist prior to treatment, or at the first trimester prenatal screening visit. Since the first antenatal visit weight is typically objectively measured, this option was prioritized if multiple weight measurements were available for a given patient, and transformed by subtracting usual average first trimester weight gain (~2 kg) (Ismail et al., 2016) to approximate pre-pregnancy weight. Self-reported weights were modified using a validated correction factor from the Canadian Health Survey (Shields et al., 2011) to account for under-reporting of weight by women (Nieto-Garcia et al., 1990) . After applying this algorithm, there were 15 270 (11.8%) records with missing BMI data in our cohort, which was similar in IVF and non-IVF women.
Study outcomes
Our primary outcome was a composite of any SMM, occurring during antenatal hospitalization or at the index birth hospitalization, defined using a modified version of the previously validated Canadian Perinatal Surveillance System outcome (Joseph et al., 2010) (Supplementary  Table S1 ). From this original definition, we excluded codes for prevalent conditions (e.g. HIV, hypertensive heart disease) in order to capture incident SMM. Transfusion codes were not available in our datasets. However, our inclusion of codes for postpartum hemorrhage ensured that relevant obstetrical conditions typically necessitating transfusion of blood products were captured. We computed the five most frequent SMM indicators in the cohort. Other pre-defined outcomes included gestational hypertension, pre-eclampsia, gestational diabetes and cesarean delivery, which were physician diagnoses recorded in obstetrical charts (Supplementary Table S2 ).
Covariates
We extracted potential confounding variables, including maternal age, ethnicity, education level, parity, reason for treatment medication use, tobacco use, alcohol consumption and illicit drug use. Pre-conception medical conditions were combined into a composite comorbidity index developed for use in obstetrics patients (Bateman et al., 2013) and validated using Canadian diagnostic codes (Metcalfe et al., 2015) (Supplementary  Table S3 ).
Statistical analysis
Participant characteristics were summarized using means and SD or median and interquartile range (IQR) for continuous variables, and counts with percentages (%) for categorical variables. We reported the total number of SMM events, with SMM rates expressed per 1000 deliveries. These were reported overall and according to the mode of conception (IVF and non-IVF) and BMI category (≥25 and <25 kg/m 2 ). The five most frequent SMM events were compared descriptively between groups. We categorized women above or below BMI of 25 kg/m 2 for our main analyses (termed high BMI, and low-normal BMI) to allow two-by-two interaction terms in multivariable models. Furthermore, increases in pregnancy morbidity are seen above this BMI, and we anticipated small numbers of obese (≥30 kg/m 2 ) IVF women over the study period. However, crude SMM rates were also provided for all BMI categories (James et al., 2012) . Univariate and multivariate log binomial regression was used to estimate crude and adjusted relative risks (RR) with 95% CI of high BMI on SMM, and separately, of IVF on SMM. A cross-product term between high BMI and IVF was included in models to assess the combined effect of both factors and the presence of multiplicative interaction. Multivariate models adjusted for age, parity, comorbidity index, neighborhood income quintile and education level. Effect modification was further assessed by evaluating heterogeneity of the effect of BMI within strata of IVF, and by computing the relative excess risk index (RERI) (RERI: RR(11) -RR(10) − RR(01) + 1, where 1 and 0 indicate exposure or not to IVF and/or high BMI) with 95% CI, to assess for additive interaction (Knol and VanderWeele, 2012) . Secondary outcomes were similarly evaluated.
We performed two sensitivity analyses. First, we attempted to evaluate outcomes according to reason for treatment (female factor, male factor and unexplained/other) where sample size permitted. Second, since low BMI may be associated with SMM (Lisonkova et al., 2017) , we re-ran multivariate models after removing women with BMI <18.5 kg/m 2 from the 'unexposed' group. Our a priori power calculation assumed a 1.5% incidence of SMM (Public Health Agency of Canada, 2013). We anticipated a 4.0-fold increase in risk in the high BMI/IVF group compared to the lownormal BMI/non-IVF group (i.e. a multiplicative effect). Extrapolating from Statistics Canada (Statistics Canada, 2015, 27 November), we further assumed that 40% of the sample would have a BMI ≥25 kg/m 2 . We expected the total number of pregnancies to be~130 000 after review of past reports from the Ontario registry, of which 2.5% (3250) were expected to be IVF births. Thus, 1300 women were expected to be jointly exposed. Using these assumptions, our study had >95% power to find a combined effect of this magnitude with two-sided alpha 0.05. It has been estimated that the sample size required to find a statistical interactive effect is higher than for a main effect (Hernandez and Blazer, 2006) , so we applied a more conservative threshold (P < 0.20) to indicate significance of cross-product terms (Selvin, 1996) . Analyses were conducted using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
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Results
Characteristics of study sample
We identified a total of 140 319 pregnancies over the study period. After exclusions, our sample included 114 409 singleton pregnancies, 1596 (1.4%) of which were following IVF (Fig. 1) . The median (±IQR) BMI was 25.3 ± 6.2 kg/m 2 , and 47 176 (41.2%) had BMI ≥25 kg/m 2 .
The proportion with high BMI was similar in IVF and non-IVF pregnancies.
The mean maternal mean age at delivery was 30.3 ± 5.2 years, and expectedly higher in IVF pregnancies (35.7 ± 4.6 years). Women pregnant by IVF were more often nulliparous, were more often in the highest income quintile, reported more years of education and were less likely to smoke (Table I) . Chronic hypertension was more common among IVF pregnancies. The comorbidity index was similar in IVF pregnancies with high BMI and IVF pregnancies with low-normal BMI (11.9 vs 9.8%, data not shown).
Male factor infertility was the most common reason for treatment, but the majority of IVF pregnancies had more than one reason for treatment. Most women with IVF pregnancies had already undergone at least one previous IVF cycle (Table I) .
Overall SMM rate and distribution of SMM indicators SMM occurred in 674 women, or 5.9/1000 deliveries. The five most common indicators were postpartum hemorrhage with embolization or ligation of pelvic vessels or suturing of the uterus (0.9/1000 deliveries), cardiac arrest (0.8/1000 deliveries), uterine rupture during labor (0.7/1000 deliveries), sepsis (0.6/1000 deliveries) and eclampsia (0.5/ 1000 deliveries). Overall, the top five SMM indicators accounted for 3.5/1000 total events (Fig. 2) .
SMM rates increased steadily in higher age categories. There were 7.8/1000 SMM events in women older than 40 years (Supplementary  Tables S4 and S5) .
SMM according to IVF status
Compared with non-IVF pregnancies (5.8 per 1000 deliveries), SMM was more frequent in IVF pregnancies (11.3 per 1000 deliveries; crude RR = 1.94, 95% CI: 1.22-3.09) (Table II) . Of the top five most common SMM indicators, uterine rupture occurred most frequently in IVF pregnancies (2.5/1000 deliveries). Event rates for cardiac arrest, puerperal sepsis and eclampsia were <1/1000 (Fig. 2) .
SMM according to BMI category
Compared with women with a low/normal BMI (5.1 per 1000 deliveries), SMM was more frequent in women with high BMI (7.0/1000 deliveries; crude RR = 1.38 (95% CI: 1.18-1.60)) (Table II) . Of the top five SMM indicators, cardiac arrest was the most frequent event in the high BMI group (1.1/1000 deliveries) (Fig. 2) . The rate and risk of SMM in the cohort increased steadily with increasing BMI (35 SMM events, or 5.0/1000 in women with BMI <18.5 kg/m 2 to 78 SMM events, or 9.2/1000 in women with BMI ≥35 kg/m 2 (Table II) ).
Outcomes according to reason for treatment
We could not stratify SMM according to reason for treatment due to small numbers. However, women with female factor infertility had higher rates of gestational hypertension, gestational diabetes and cesarean delivery than women who used IVF due to male factor infertility. The proportion with pre-eclampsia was similar regardless of cause of infertility (Table III, Supplementary Tables S6 and S7 ). Adjusted risk of SMM and other outcomes due to individual and joint effects of high BMI and IVF
The absolute risk of SMM was highest among women pregnant by IVF with a low-normal BMI (12.4 per 1000), and not among women pregnant by IVF with high BMI (i.e. jointly exposed) (9.6 per 1000; Table IV ). After adjusting for age, parity, income, education and baseline comorbidity, IVF was associated with a nearly 2-fold increased risk of SMM among women with low-normal BMI (aRR = 1.89, 95% CI: 1.06-3.39). Having a high BMI also independently conferred a modest increased risk for SMM (aRR = 1.23, 95% CI: 1.04-1.45) when compared to women with low-normal BMI. However, the joint effect of both IVF and high BMI did not exceed multiplication of individual risks, indicating no interaction on the multiplicative scale. Similarly, the RERI also indicated sub-additive interaction. The absolute risks of gestational hypertension, pre-eclampsia, gestational diabetes and cesarean delivery were highest in women pregnant by IVF with high BMI compared to women without IVF and women with low-normal BMI. Interactive effects were mostly sub-multiplicative and approximately additive for these outcomes (Table IV) .
The joint effect of high BMI and IVF on secondary outcomes was more pronounced with male factor infertility. The results were unchanged when restricting our analyses to women with BMI > 18.5 kg/m 2 (Supplementary Table S8 ).
Discussion
In this contemporary population-level analysis of 114 409 singleton births in Ontario, Canada, IVF pregnancy was approximately twice as likely to be complicated by SMM, in particular uterine rupture, eclampsia, sepsis, cardiac arrest and embolization or ligation of pelvic vessels or suturing of the uterus. Dataset privacy restrictions precluded formal statistical assessment of these individual indicators. While women with an elevated pre-pregnancy BMI were also at risk of SMM, with a dose response with increasing BMI, we did not observe evidence of a joint effect of both high BMI and IVF on SMM risk. Our finding that IVF increases the risk of SMM is similar to previous reports (Belanoff et al., 2016 , Martin et al., 2016 , Wang et al., 2016 . There are several potential explanations. First, women who require IVF differ from women who conceive without reproductive assistance in that they are older, more often nulliparous, may have age-related health conditions and are more often pregnant with multiples. In our cohort, we removed multiple gestations, and adjusted for age, parity and the comorbidity index. The reason for treatment may play a role; specifically, severity of infertility contributes to poor outcomes (Basso et al., 2003 , Messerlian et al., 2012 (Thomson et al., 2005) . While we were unable to analyze SMM according to reason for treatment, our stratified analysis of secondary outcomes suggests a potential mediating effect.
It is possible that treatment itself may predispose women to SMM, via impaired endometrial receptivity resulting from repeated cycles of ovarian stimulation (Nakamura et al., 1997) . The abnormal trophoblastic invasion in a host with a poorly receptive endometrium can manifest later with bleeding, premature placental detachment or severe pre-eclampsia (Chen et al., 2016) . Our study was not designed to evaluate mechanisms, and only a randomized design would be able to clarify whether treatment contributes to poor maternal outcomes.
Overweight and obesity is associated with insulin resistance and subclinical inflammation, predisposing to cardiovascular complications and other morbidities (Catalano, 2010) . Our finding of higher SMM in women with elevated BMI is consistent with past reports. A nationwide case-control study in the Netherlands reported a 30% increase in the risk of SMM in low-risk overweight individuals compared to normal-weight women (Witteveen et al., 2013) and also found a dose-response effect.
The lack of synergy of both factors on SMM risk may reflect more careful selection of overweight and obese women for fertility therapy by reproductive clinicians: our data showed no significant difference in baseline comorbidity in IVF-treated women in either BMI category, whereas in unselected populations, the rate of morbidity may be expected to be significantly higher in women with high BMI. Furthermore, perhaps overweight and obese women are treated with more conservative approaches. Type II (beta) error may also explain the lack of a supra-additive effect of IVF and high BMI on SMM. In our study, the post-hoc Type II error, or false negative rate, is estimated to be 25% accounting for the lower than expected proportion of IVF pregnancies and lower than expected SMM rate. Finally, the absolute event rate of SMM (5.9/1000 deliveries) is lower than what has been reported by the Canadian Perinatal Surveillance System (15.1/1000 in 2011) (Public Health Agency of Canada, 2013). This discrepancy is likely accounted for by minor modifications we made to the Canadian SMM definition in order to capture incident morbid events. Furthermore, we lacked transfusion codes, but morbid events associated with transfusions (e.g. uterine rupture, postpartum hemorrhage) were captured using our approach.
Absolute risks for gestational hypertension, pre-eclampsia, gestational diabetes and cesarean delivery were highest among overweight/ obese women who conceived using IVF. This translated to a supraadditive interaction for the outcomes pre-eclampsia and gestational diabetes, and near additive interaction for gestational hypertension and cesarean delivery. We previously showed a supra-additive effect of high BMI and IVF on pre-eclampsia risk in a single-center study (Dayan et al., 2014) . Others have reported an augmented risk of gestational diabetes in overweight/obese women pregnant by IVF, suggesting increased metabolic demands of infertility and its treatment (Cai et al., 2017) .
Our findings should be considered hypothesis generating, given potential biases inherent in observational studies. First, the relatively small number of women who used IVF in this one-year cohort did not allow extensive exploration of outcomes according to reason for treatment, which is an important mediating variable. Second, BMI was partially derived by self-report which may lend itself to non-differential misclassification. Misclassification is likely minimal, since the proportion of women who were overweight or obese was similar to that in Statistics Canada reports (Statistics Canada, 2015, November 27 ). We applied a validated bias correction factor to correct for underreporting (Shields et al., 2011) . Finally, while we adjusted for known confounders, residual confounding is possible.
Despite these limitations, this study was unique in its design and aim, which is to specifically evaluate whether women with high BMI have poorer pregnancy outcomes after IVF. We used a large, comprehensive dataset with high data completeness and accuracy, and used bias correction analyses to minimize misclassification and confounding. Given the high population prevalence of obesity, large administrative health datasets are effective tools to assess its impact on maternal outcomes in IVF and non-IVF pregnancies, since long-term prospective studies would be difficult, costly and time consuming. 
Continued
Conclusion
Women pregnant by IVF are at increased risk of SMM compared to women pregnant without IVF, but this risk is not compounded by high BMI. There may be a supra-additive risk of gestational diabetes and pre-eclampsia in women with high BMI who use IVF. Overweight and obese women who seek fertility therapy should be counseled about these potential risks, and efforts should be taken to achieve a normal body weight pre-conception. The decision to proceed with IVF should be based on clinical judgment after considering an individual's chance of success and risk of SMM.
Supplementary data
Supplementary data are available at Human Reproduction online. Measure of interaction on the additive scale: RERI (95% CI) = −0.17 (−0.37, 0.02) Table IV reports frequencies, event rates (expressed per 1000 or per 100), stratified according to IVF status (column), and BMI category (row). Adjusted relative risks are shown for individual (IVF only) and combined (IVF and high BMI) effects. On the far right, heterogeneity of the effect of BMI within IVF vs no IVF category is shown. Multiplicative interaction is considered if the RR of both factors exceeds multiplication of individual risks, and if clear heterogeneity of the effect is found. Additive interaction is considered if the RERI is above zero Knol and VanderWeele 2012) . Models adjusted for age, parity, education level, income quintile and maternal comorbidity index (Metcalfe, Br J Obstet Gynecol 2015) . Abbreviations: aRR, adjusted relative risk; RERI, relative excess risk index; SMM, severe maternal morbidity; IVF, in-vitro fertilization.
